Ocular Inflammation:治療薬開発パイプライン分析2014

◆英語タイトル:Ocular Inflammation-Pipeline Insights, 2014
◆商品コード:DIPR2014486
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2014年版(※最新版はお問い合わせください)
◆ページ数:※お問い合わせください。
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥136,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

SUMMARY
DelveInsight’s,“ Ocular Inflammation-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Ocular Inflammation. This report provides information on the therapeutic development based on the Ocular Inflammation dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.


Scope
• The report provides a snapshot of the global therapeutic landscape of Ocular Inflammation
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Ocular Inflammation pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Ocular Inflammation and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
• Complete Pipeline intelligence and complete understanding over therapeutics development for Ocular Inflammation
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Ocular Inflammation pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions


【レポートの目次】

Table of Contents
• Ocular Inflammation Overview
• Ocular Inflammation Pipeline Therapeutics
• Ocular Inflammation Therapeutics under Development by Companies
• Ocular Inflammation Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Ocular Inflammation Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Ocular Inflammation Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Ocular Inflammation Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Ocular Inflammation – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Ocular Inflammation – Discontinued Products
• Ocular Inflammation – Dormant Products
• Companies Involved in Therapeutics Development for Ocular Inflammation
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Ocular Inflammation, 2014
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
• Drug Candidates Profiles
• Ocular Inflammation Assessment by Monotherapy Products
• Ocular Inflammation Assessment by Combination Products
• Ocular Inflammation Assessment by Route of Administration
• Ocular Inflammation Assessment by Stage and Route of Administration
• Ocular Inflammation Assessment by Molecule Type
• Ocular Inflammation Assessment by Stage and Molecule Type
• Ocular Inflammation Therapeutics – Discontinued Products
• Ocular Inflammation Therapeutics – Dormant Products
• Products under Development by Companies, 2014


List of Figures
• Number of Products under Development for Ocular Inflammation, 2014
• Late Clinical Stage Products (Filed and Phase III), 2014
• Mid Clinical Stage Products (Phase II), 2014
• Early Clinical Stage Products (Phase I and IND Filed), 2014
• Discovery and Pre-Clinical Stage Products, 2014
• Ocular Inflammation Assessment by Monotherapy Products
• Ocular Inflammation Assessment by Combination Products
• Ocular Inflammation Assessment by Route of Administration
• Ocular Inflammation Assessment by Stage and Route of Administration
• Ocular Inflammation Assessment by Molecule Type
• Ocular Inflammation Assessment by Stage and Molecule Type


【レポートのキーワード】

Ocular Inflammation、病、治療薬、研究開発、パイプライン、製薬企業、臨床、医薬品

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Ocular Inflammation:治療薬開発パイプライン分析2014]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆